RAPT Therapeutics (NASDAQ:RAPT) Announces Quarterly Earnings Results

RAPT Therapeutics (NASDAQ:RAPT) released its quarterly earnings data on Thursday. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69), Zacks reports.

RAPT Therapeutics Price Performance

RAPT opened at $1.12 on Friday. The business has a fifty day simple moving average of $1.26 and a 200 day simple moving average of $1.57. The company has a market capitalization of $39.15 million, a PE ratio of -0.40 and a beta of -0.31. RAPT Therapeutics has a 1 year low of $0.79 and a 1 year high of $10.05.

Wall Street Analyst Weigh In

Several research analysts have issued reports on RAPT shares. Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $8.00 to $2.00 in a research note on Monday, November 11th. Wells Fargo & Company dropped their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Thursday, December 26th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $5.29.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.